Target PSMAClass Small molecule (urea, DOTAGA chelator)Other names zadavotide guraxetan
Structure from the cited PubChem record (unlabelled ligand, or the labelled form when PubChem only describes that one). Conformer: RDKit (computed conformer, indicative). Rotate with the mouse or a finger.
| Form | Use | Molar mass (labelled form) | Ongoing trials | Most advanced phase | Approval |
|---|---|---|---|---|---|
| [¹⁷⁷Lu]Lu-PSMA-I&T Syntheses and QC ↗ | Therapy | 1,672.3 | 18 | Phase 3 | — |
| [²²⁵Ac]Ac-PSMA-I&T Syntheses and QC ↗ | Therapy | — | 7 | Phase 3 | — |
| [¹⁶¹Tb]Tb-PSMA-I&T Syntheses and QC ↗ | Therapy | — | 4 | Phase 2 | — |
| [⁶⁸Ga]Ga-PSMA-I&T Syntheses and QC ↗ | Imaging | — | 0 | — | — |
Atlas trials whose studied drug or title names this vector, with this radionuclide.
| Trial | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
| VECTRA-01 · [225Ac]AZD2265 (ex-FPI-2265, PSMA-I&T)NCT07611110 · Prostate – mCRPC | Phase 3 | Recruiting | AstraZeneca | 24 |
| SPLASH · [177Lu]Lu-PSMA-I&T (PNT2002/zadavotide)NCT04647526 · Prostate – mCRPC | Phase 3 | Active, not recruiting | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | 6 |
| [177Lu]PSMA-I&TNCT05204927 · Prostate – mCRPC | Phase 3 | Active, not recruiting | Curium US LLC | 4 |
| [177Lu]PSMA-I&T2022-500570-33-00 · Prostate – other | Phase 3 | Recruiting | Region Västerbotten, Umea University | 1 |
| PROSPECTOR · [225Ac]AZD2265 (ex-FPI-2265, PSMA-I&T)NCT07590934 · Prostate – other | Phase 2 | Recruiting | AstraZeneca | 7 |
| AlphaBreak · [225Ac]AZD2265 (ex-FPI-2265, PSMA-I&T)NCT06402331 · Prostate – mCRPC | Phase 2 | Active, not recruiting | Fusion Pharmaceuticals Inc. | 1 |
| LUNAR · [177Lu]Lu-PSMA-I&T (PNT2002/zadavotide)NCT05496959 · Prostate – localised / recurrence | Phase 2 | Active, not recruiting | Jonsson Comprehensive Cancer Center | 1 |
| LUST · [177Lu]PSMA-I&TNCT05893381 · Prostate – localised / recurrence | Phase 2 | Recruiting | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 1 |
| PRODIGY-1 · [177Lu]PSMA-I&TNCT05896371 · Prostate – other | Phase 2 | Not yet recruiting | CHU de Quebec-Universite Laval | 0 |
| TATCIST · [225Ac]AZD2265 (ex-FPI-2265, PSMA-I&T)NCT05219500 · Prostate – mCRPC | Phase 2 | Active, not recruiting | Fusion Pharmaceuticals Inc. | 1 |
| [225Ac]AZD2265 (ex-FPI-2265, PSMA-I&T)NCT06909825 · Prostate – mCRPC | Phase 2 | Active, not recruiting | Fusion Pharmaceuticals Inc. | 1 |
| TeLuNa · [161Tb]/[177Lu]PSMA-I&TNCT07441837 · Prostate – mCRPC | Phase 2 | Not yet recruiting | Ankara University | 1 |
| LUBASKET · [177Lu]PSMA-I&TNCT05867615 · Solid tumors (multiple indications) | Phase 2 | Active, not recruiting | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 1 |
| [177Lu]PSMA-I&T2026-527110-23-00 · Prostate – mCRPC | Phase 2 | Not yet recruiting | Region Uppsala | 1 |
| [177Lu]PSMA-I&TNCT06220188 · Prostate – localised / recurrence | Phase 2 | Recruiting | Medical University of Vienna | 1 |
| AlphaBet · [177Lu]PSMA-I&TNCT05383079 · Prostate – mCRPC | Phase 2 | Active, not recruiting | Peter MacCallum Cancer Centre, Australia | 1 |
| [177Lu]PSMA-I&T2023-504696-24-00 · Brain (glioma, medulloblastoma…) | Phase 2 | Not yet recruiting | Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) | 2 |
| VIOLET · [161Tb]PSMA-I&TNCT05521412 · Prostate – mCRPC | Phase 2 | Recruiting | Peter MacCallum Cancer Centre, Australia | 1 |
| [177Lu]PSMA-I&TNCT06259123 · Prostate – localised / recurrence | Phase 2 | Recruiting | Medical University of Vienna | 1 |
| [177Lu]PSMA-I&T2026-526519-12-00 · Prostate – mCRPC | Phase 2 | Not yet recruiting | Universitetssykehuset Nord-Norge HF | 1 |
| PROGNOSTICS · [161Tb]/[177Lu]PSMA-I&TNCT06343038 · Prostate – mCRPC | Phase 1 | Recruiting | University Hospital, Basel, Switzerland | 1 |
| LumOnate · [177Lu]PSMA-I&TNCT07090369 · Prostate – mCRPC | Phase 1 | Not yet recruiting | Peter MacCallum Cancer Centre, Australia | 1 |
| [177Lu]Lu-PSMA-617 (Pluvicto)NCT04886986 · Prostate – mCRPC | Phase 1 | Recruiting | Weill Medical College of Cornell University | 1 |
| [225Ac]PSMA-I&T2024-513729-22-01 · Prostate – other | Phase 1 | Recruiting | Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) | 1 |
| [177Lu]PSMA-I&TNCT07316686 · Prostate – mCRPC | Phase 1 | Recruiting | Instituto do Cancer do Estado de São Paulo | 1 |
| [161Tb]PSMA-I&TNCT07621692 · Prostate – mCRPC | Phase 1 | Recruiting | National Taiwan University Hospital | 1 |
| 2026-10 | LUNAR (extended follow-up) · positiveTwo cycles of ¹⁷⁷Lu-PSMA before stereotactic radiotherapy of hormone-sensitive oligorecurrence: progression-free survival of 17.6 vs 7.4 months (HR 0.38) and delayed need for hormone therapy, with 32 months of follow-up. | Eur Urol ↗ |
| 2026-06 | Lu-PSMA + capecitabine · earlyNo limiting toxicity up to 1,000 mg/m² of capecitabine (12 patients); PSA50 of 50%. A signal to confirm in a larger cohort. | Eur J Nucl Med Mol Imaging ↗ |
247 publications in PubMed for the query below; the most recent:
"PSMA I&T"[tiab] OR "PSMA-I&T"[tiab] OR zadavotide[tiab]
Sources: PubChem and PubMed (NCBI), ClinicalTrials.gov and CTIS registries, approvals recorded by the atlas. PubChem data as of 28 October 2026.
PSMA-I&T. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 27 October 2026. https://theranosticatlas.com/molecule/psma-it/ (accessed [date]).
A monitoring tool with no regulatory value: check every item at its source.